ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Clinical trials for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) explained in plain language.
Never miss a new study
Get alerted when new ADVANCED HEPATOCELLULAR CARCINOMA (HCC) trials appear
Sign up with your email to follow new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo aims to outperform standard care in advanced liver cancer
Disease control CompletedThis phase 3 trial compares a combination of two drugs—toripalimab (an immunotherapy) and bevacizumab (an anti-angiogenic agent)—against the standard drug sorafenib as the first treatment for people with advanced liver cancer that cannot be surgically removed. The study enrolls a…
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Phase: PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Immunotherapy combo aims to shrink advanced liver tumors
Disease control CompletedThis phase 2 trial investigates whether combining toripalimab (an immunotherapy) with bevacizumab (a drug that cuts off tumor blood supply) can safely shrink advanced liver cancer when used as the first treatment. About 50 to 60 adults with intermediate or late-stage liver cancer…
Matched conditions: ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC